Trials / Withdrawn
WithdrawnNCT02155634
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see how long lenalidomide therapy can maintain or improve the disease response obtained after induction therapy that does not include lenalidomide, pomalidomide or thalidomide; and consequently reduce worsening of disease and to evaluate the activity of lenalidomide. Patients will receive lenalidomide or be under observation. All patients will attend regular clinic visits to evaluate their disease and health. Patients will have the option to participate in additional biomarker correlative studies in addition to their participation in the main study.
Conditions
- Multiple Myeloma
- Neoplasms
- Plasma Cells
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases
- Therapeutic Uses
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-04-01
- Completion
- 2021-03-01
- First posted
- 2014-06-04
- Last updated
- 2018-04-10
Source: ClinicalTrials.gov record NCT02155634. Inclusion in this directory is not an endorsement.